Etrasimod for Alopecia Areata

Phase 2

Waitlist Available

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up ole period: from first dosing date in ole up to last dosing date + 4 weeks + 3 days (maximum up to 33 weeks)

Summary

This trial is testing the safety and effectiveness of etrasimod, a medication taken alone, in people with significant hair loss due to alopecia areata. The drug works by adjusting the immune system to help reduce hair loss.

Eligible Conditions

Alopecia Areata

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ db treatment period: from first dosing date in db up to (before the first dosing date in ole) or (last dosing date + 4 weeks + 3 days), whichever is earlier (maximum up to 29 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~db treatment period: from first dosing date in db up to (before the first dosing date in ole) or (last dosing date + 4 weeks + 3 days), whichever is earlier (maximum up to 29 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and db treatment period: from first dosing date in db up to (before the first dosing date in ole) or (last dosing date + 4 weeks + 3 days), whichever is earlier (maximum up to 29 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period

Secondary study objectives

Change From Baseline in SALT I at Week 24: DB Treatment Period

Percentage of Participants Who Achieved Greater Than or Equal to (>=) 30%, >= 50% and >=75% Improvement From Baseline in SALT I at Week 24: DB Treatment Period

Other study objectives

Number of Participants With Adverse Events (AE): DB Treatment Period

Number of Participants With Adverse Events: OLE Period